ADC Therapeutics SA Files 8-K on Sept 30, 2025

Ticker: ADCT · Form: 8-K · Filed: Sep 30, 2025 · CIK: 1771910

Adc Therapeutics SA 8-K Filing Summary
FieldDetail
CompanyAdc Therapeutics SA (ADCT)
Form Type8-K
Filed DateSep 30, 2025
Risk Levellow
Pages2
Reading Time2 min
Sentimentneutral

Sentiment: neutral

Topics: corporate-disclosure, 8-K

TL;DR

ADC Therapeutics SA filed an 8-K on 9/30/25 with corporate address and contact info.

AI Summary

ADC Therapeutics SA filed an 8-K on September 30, 2025, reporting information under Regulation FD Disclosure and Financial Statements and Exhibits. The filing details the company's principal executive offices located at Biopôle, Route de la Corniche 3B, 1066 Epalinges, Switzerland, and provides its telephone number as +41 21 653 02 00.

Why It Matters

This 8-K filing serves as a public record of ADC Therapeutics SA's corporate information and regulatory disclosures as of September 30, 2025.

Risk Assessment

Risk Level: low — This filing is a routine corporate disclosure and does not contain information that inherently increases risk.

Key Players & Entities

  • ADC Therapeutics SA (company) — Registrant
  • September 30, 2025 (date) — Date of Report
  • Biopôle Route de la Corniche 3B 1066 Epalinges Switzerland (address) — Principal Executive Offices
  • +41 21 653 02 00 (phone_number) — Registrant's Telephone Number

FAQ

What is the exact name of the registrant as specified in its charter?

The exact name of the registrant is ADC Therapeutics SA.

On what date was this 8-K report filed?

The report was filed on September 30, 2025.

Where are ADC Therapeutics SA's principal executive offices located?

The principal executive offices are located at Biopôle Route de la Corniche 3B, 1066 Epalinges, Switzerland.

What is the registrant's telephone number?

The registrant's telephone number is +41 21 653 02 00.

Under which sections of the Securities Exchange Act of 1934 is this report filed?

This report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

Filing Stats: 500 words · 2 min read · ~2 pages · Grade level 10.1 · Accepted 2025-09-30 09:16:20

Filing Documents

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. On September 30, 2025, ADC Therapeutics SA (the "Company") made available an updated corporate presentation. A copy of the corporate presentation is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein. The information contained in these Items and Exhibit 99.1 shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Corporate presentation 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ADC Therapeutics SA Date: September 30, 2025 By: /s/ Peter J. Graham Name: Peter J. Graham Title: Chief Legal Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.